Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
34 studies found for:    " December 08, 2010":" January 07, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" December 08, 2010":" January 07, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines
Condition: HIV Infections
Interventions: Biological: Adjuvanted GSK investigational HIV vaccine formulation 1;   Biological: Adjuvanted GSK investigational HIV vaccine formulation 2;   Biological: Ad35 investigational HIV vaccine;   Biological: Placebo (saline)
2 Completed Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
3 Completed
Has Results
Two Approaches to Routine HIV Testing in a Hospital Emergency Department
Condition: HIV Infections
Interventions: Procedure: Oral HIV screening;   Procedure: Fingerstick HIV screening
4 Completed The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
Condition: HIV Infection
Intervention: Drug: Efavirenz
5 Completed Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults
Condition: HIV Infections
Interventions: Biological: Profectus HIV MAG pDNA vaccine;   Biological: IL-12;   Other: Placebo
6 Completed Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
Condition: HIV Infection
Interventions: Drug: Aprepitant;   Drug: Aprepitant placebo
7 Completed TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir
Condition: HIV Infections
Interventions: Drug: TMC278;   Drug: Raltegravir
8 Completed Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
Condition: HIV Infection
Intervention: Biological: Fluzone®
9 Completed The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
Condition: HIV Infection
Intervention: Drug: Efavirenz
10 Unknown  Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Conditions: Children With Confirmed HIV Infection;   Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose;   Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
Intervention: Drug: Mycobutin
11 Completed Recovery Management Intervention in China
Conditions: Methadone;   HIV Infections
Intervention: Behavioral: Recovery management
12 Withdrawn A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572;   Drug: GSK2248761
13 Active, not recruiting Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Condition: HIV Dementia
Intervention: Drug: Atorvastatin
14 Completed Study of SystemCHANGE-HIV
Condition: HIV
Intervention: Behavioral: SystemCHANGE-HIV
15 Completed Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients
Condition: HIV
Intervention: Drug: Etoricoxib
16 Completed
Has Results
Effects of Growth Hormone Releasing Hormone in HIV
Conditions: HIV;   HIV Lipodystrophy
Interventions: Drug: tesamorelin;   Drug: placebo
17 Recruiting A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Condition: HIV
Interventions: Drug: PRO 140;   Drug: Placebo
18 Completed
Has Results
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
Condition: HIV
Interventions: Drug: Tenofovir/emtricitabine;   Drug: Tenofovir/emtricitabine/efavirenz;   Drug: Raltegravir
19 Completed A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
Condition: HIV
Interventions: Drug: TMC278;   Drug: Efavirenz
20 Completed Preparing for International Prevention Trials Involving HIV-Infected Individuals in Care Settings
Condition: HIV
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.